Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4910MR)

This product GTTS-WQ4910MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4910MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6306MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ12223MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ13513MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ421MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ1213MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ9822MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ9569MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15213MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW